Clinical trial · Interventional
To Evaluate the Clinical Efficacy of Probiotics in Patients With the Breast Cancer
To Evaluate the Efficacy of Probiotics in Improvement and Prevention of Chemotherapy Associated Side Effectes in Patients With the Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Chemotherapy-associated side-effects would affect therapeutic effect, quality of life, and cause permanent harm to breast cancer patients. This study is designed to explore after consumption of probiotics of lactobacillus composite strain powder sachets for 6 months in breast cancer chemotherapy, and whether the improvement of meliorate the side effects, further assists patients completing the chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Other | — | UNRESOLVED |
| Probiotic | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Probiotic group
- description
- Subjects received two probiotic sachets per day
- interventionNames
- Dietary Supplement: Probiotic
- type
- PLACEBO_COMPARATOR
- label
- Placebo group
- description
- Subjects received two placebo sachets per day
- interventionNames
- Other: Placebo
Primary outcomes (1)
- measure
- Change from 12 weeks in the chemotherapy associated side-effects questionnaire at 24 weeks
- timeFrame
- 24 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Stage I-III breast patients using anthracycline-based and taxane-based chemotherapy (not limited before or after chemotherapy/surgery) * BMI \> 18 kg/m\^2 * Age between 20 and 80 years old * Patients judged by physicians to participate in this trial and who are willing Exclusion Criteria: * Pregnant or lactating female patients * Patients with bariatric surgery, gastrointestinal resections, Crohn's disease, celiac disease * BMI \< 18 kg/m\^2 * Patient who have severe allergy to soybeans or peanuts * Those who are under 20 years old or over 80 years old
References
Publications (0)
Data not yet available